HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.

Abstract
Dinapsoline is a new potent, full agonist at D1 dopamine receptors with limited selectivity relative to D2 receptors. The efficacy of this compound was assessed in rats with unilateral 6-hydroxydopamine lesions of the medial forebrain bundle, a standard rat model of Parkinson's disease. Dinapsoline produced robust contralateral rotation after either subcutaneous or oral administration. This rotational behavior was attenuated markedly by the D1 receptor antagonist SCH-23390, but not by the D2 receptor antagonist raclopride. During a chronic 14-day treatment period in which rats received dinapsoline either once or twice a day, dinapsoline did not produce tolerance (in fact, some sensitization of the rotational response was observed in one experiment). Because dinapsoline shows less D1:D2 selectivity in vitro than other D1 agonists, the contribution of D2 activity to tolerance was assessed. Chronic daily cotreatment with dinapsoline and raclopride did not enable the development of tolerance to chronic dinapsoline treatment. In contrast, when dinapsoline was administered by osmotic minipump, rapid tolerance was observed. To explore further the contribution of D1 and D2 receptors to tolerance, experiments were performed with the selective D1 agonist A-77636. Daily dosing with A-77636 rapidly produced complete tolerance, as previously observed, whereas coadministration of the D2 agonist quinpirole plus A-77636 failed to either delay or prevent tolerance. Taken together, these results indicate that the development of tolerance to D1 receptor agonists is influenced by the pattern of drug exposure but not by the D1:D2 selectivity of the agonist.
AuthorsA G Gulwadi, C D Korpinen, R B Mailman, D E Nichols, S Y Sit, M T Taber
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 296 Issue 2 Pg. 338-44 (Feb 2001) ISSN: 0022-3565 [Print] United States
PMID11160615 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antiparkinson Agents
  • Dopamine Agonists
  • Hydroxydopamines
  • Isoquinolines
  • Naphthols
  • Receptors, Dopamine D1
  • dinapsoline
  • Quinpirole
  • Raclopride
  • Dopamine
Topics
  • Animals
  • Antiparkinson Agents (therapeutic use)
  • Chromatography, High Pressure Liquid
  • Dopamine (metabolism)
  • Dopamine Agonists (therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Tolerance
  • Hydroxydopamines
  • Isoquinolines (therapeutic use)
  • Male
  • Naphthols (therapeutic use)
  • Neostriatum (drug effects, metabolism)
  • Parkinson Disease (drug therapy)
  • Quinpirole (therapeutic use)
  • Raclopride (therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Dopamine D1 (agonists)
  • Rotation
  • Stereotyped Behavior (drug effects)
  • Sympathectomy, Chemical

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: